GENE ONLINE|News &
Opinion
Blog

2023-06-28| R&D

Gut Microbiome Composition Offers Insights for Diagnosis and Intervention of Early Alzheimer’s Disease

by Richard Chau
Share To
Even at the earliest (preclinical) stage of AD, when the affected individuals remain cognitively intact with no apparent neurodegeneration, changes in the brain are already occurring. These changes include the accumulation of proteins called amyloid beta (Aβ) and tau.

There is a growing consensus that therapeutic intervention should be initiated at this stage for meaningful disease modification in AD. Thanks to evolving research on biomarkers related to AD pathology, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. 

It's free! Log in now to read

LATEST
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
2024-05-23
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
GV Announces Cooperation with CICC
2024-05-22
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
EVENT
Scroll to Top